8-K: Salarius Completes Decoy Merger, Secures $6.3M in Offering

Salarius Pharmaceuticals completed its merger with Decoy Therapeutics and raised approximately $6.3 million in net proceeds from a public offering of common stock and warrants to fund clinical development and general corporate purposes.

Summary

• Salarius Pharmaceuticals, Inc. completed its merger with Decoy Therapeutics Inc. on November 12, 2025, resulting in Decoy becoming a wholly-owned subsidiary.
• The company completed a public offering, raising approximately $6.3 million in net proceeds after deducting underwriting discounts, commissions, and other estimated offering expenses.
• The offering included 2,514,335 shares of common stock, pre-funded warrants to purchase up to 2,152,331 shares of common stock, Series A warrants to purchase up to 4,666,666 shares of common stock, and Series B warrants to purchase up to 4,666,666 shares of common stock.
• The combined public offering price was $1.50 per share of common stock with accompanying Series A and B warrants, and $1.4999 per pre-funded warrant with accompanying Series A and B warrants.
• The underwriter exercised its 45-day option on November 11, 2025, for an additional 665,729 shares of Common Stock, Series A warrants to purchase up to 699,999 shares, and Series B warrants to purchase up to 699,999 shares.
• Net proceeds will be used primarily to advance the clinical development of the combined company's research and development programs, pay off certain of Decoy's outstanding promissory notes, and for other general corporate purposes, including working capital and capital expenditures.
• Series A warrants have an exercise price of $1.50 per share and expire in five years; Series B warrants have an exercise price of $1.50 per share and expire in one year. Pre-funded warrants have an exercise price of $0.0001 per share and are exercisable until fully exercised.
• Immediately after closing the offering, there were 4,231,846 shares of Common Stock and pre-funded warrants to acquire an additional 2,152,331 shares of Common Stock outstanding.
• In connection with the merger, Salarius issued 877.709 shares of Series A Non-Voting Convertible Preferred Stock and 796.306 shares of Series B Non-Voting Convertible Preferred Stock to former Decoy stockholders and debtholders.
• An anti-dilution adjustment, triggered by the offering's effective price being below the $3.75 floor price, reset the conversion ratio for the Series A and B Preferred Stock to 2,800-1, resulting in 4,814,106 common shares underlying the preferred stock.
• Conversion of the preferred stock into common stock requires stockholder approval in accordance with Nasdaq Rule 5635 and approval of the company's initial listing application with Nasdaq.

Sentiment

Score: 4

Explanation: While the merger with Decoy Therapeutics and the capital raise provide a new strategic direction and funding for innovative R&D, the significant dilution from the public offering and the anti-dilution adjustment for preferred stock conversion are substantial negatives for existing common shareholders. The company's future success hinges on the unproven IMP3ACT platform and clinical development milestones, which carry high inherent risks in the biotech sector.

Positives

• Successful completion of the strategic merger with Decoy Therapeutics, integrating AI/ML drug discovery capabilities into the combined entity.
• The public offering successfully raised approximately $6.3 million in net proceeds, providing capital to fund clinical development and general corporate purposes.
• The new management team, largely from Decoy, brings expertise in biotech entrepreneurship, scientific development, and business strategy, which is critical for the combined company's new focus.
• Decoy's pipeline includes promising assets such as a pan-coronavirus antiviral, a broad-acting antiviral for flu/COVID-19/RSV, and a peptide drug conjugate for GI cancers, with an Investigational New Drug (IND) application for the lead asset expected within 12 months.
• Decoy previously secured significant non-dilutive capital from various sources, including the Massachusetts Life Sciences Seed Fund, Google AI startup program, NVIDIA Inception program, and a BARDA QuickFire Challenge award, indicating external validation of its technology and potential.

Negatives

• The public offering resulted in significant dilution for existing common stockholders due to the issuance of common stock and a substantial number of warrants.
• The effective per share price of the offering ($1.50) was below the $3.75 floor price for preferred stock conversion, triggering an anti-dilution adjustment that reset the conversion ratio to 2,800-1, leading to greater potential dilution from preferred stock conversion for existing common shareholders.
• The Series B warrants have a short one-year expiry, which could lead to forced exercise or expiration, potentially impacting market dynamics.
• The Series A and B Preferred Stock issued in the merger are not immediately convertible into common stock, requiring future stockholder approval and Nasdaq listing approval, which introduces uncertainty and potential delays for former Decoy holders.
• There is no trading market available for the warrants on any securities exchange or nationally recognized trading system, limiting liquidity for warrant holders.

Risks

• Risks related to the combined company's ability to satisfy the initial listing standards of Nasdaq in the required timeframe.
• Risks that the combined company will not achieve the synergies expected from the proposed merger.
• Risks that the combined company will not obtain sufficient financing to execute on its business plans.
• Risks that Salarius will be unable to obtain stockholder approval for the conversion of the preferred stock.
• Risks related to the combined company's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP3ACT platform.
• Political uncertainties, stock price volatility, and uncertainties relating to the financial markets, the medical community, and the global economy.
• The impact of instability in general business and economic conditions, including changes in inflation, interest rates, and the labor market.

Future Outlook

The combined company, which will be renamed Decoy Therapeutics, plans to advance its lead asset, a pan-coronavirus antiviral, to an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) within the next 12 months. It also expects to make progress on other programs, including a novel broad-acting antiviral to treat flu, COVID-19, and respiratory syncytial virus (RSV), and a peptide drug conjugate targeting GI cancers. The company anticipates multiple value-creating inflection points in the coming year.

Management Comments

• "I'd like to thank both the Salarius and Decoy teams for their hard work and dedication in completing this transaction, which supports the advancement of next-generation therapeutics through our proprietary IMP3ACT Platform." Frederick Rick Pierce, Chief Executive Officer of Salarius.
• "By combining artificial intelligence (AI), machine learning (ML) and high-speed synthesis techniques, we rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs." Frederick Rick Pierce, Chief Executive Officer of Salarius.
• "Our technology and innovations in manufacturing allow for advancing new therapies from lab to clinic to commercialization with unprecedented speed." Frederick Rick Pierce, Chief Executive Officer of Salarius.
• "We anticipate multiple value-creating inflection points in the coming year, initially targeting unmet needs in respiratory infectious diseases and gastroenterology (GI) oncology indications." Frederick Rick Pierce, Chief Executive Officer of Salarius.

Industry Context

The merger positions the combined entity, soon to be Decoy Therapeutics, at the forefront of biotechnology and advanced computational methods (AI/ML) for drug discovery. This approach, leveraging high-speed synthesis for peptide conjugate therapeutics, aligns with a growing industry trend towards accelerating drug development and addressing unmet medical needs more efficiently. Decoy's focus on antivirals (pan-coronavirus, flu, COVID-19, RSV) and GI cancers targets significant global health challenges and highly competitive therapeutic areas. The non-dilutive funding from entities like the Massachusetts Life Sciences Seed Fund, Google AI startup program, NVIDIA Inception, and BARDA's BLUE KNIGHT initiative highlights the industry's recognition of AI/ML's potential in drug development and the strategic importance of these therapeutic areas.

Comparison to Industry Standards

• The combined company's emphasis on leveraging AI/ML and high-speed synthesis through its IMP3ACT platform for drug design and manufacturing represents a cutting-edge approach in the biopharmaceutical industry, aiming for accelerated development timelines compared to traditional methods.
• Decoy's success in attracting non-dilutive capital from prominent sources such as the Massachusetts Life Sciences Seed Fund, Google AI startup program, NVIDIA Inception, and BARDA's BLUE KNIGHT program indicates strong external validation of its technology and pipeline potential, comparable to other innovative biotech startups that secure significant early-stage funding and strategic partnerships.
• The goal of filing an IND application for its lead pan-coronavirus antiviral asset within 12 months is an ambitious yet achievable milestone for a preclinical-stage company utilizing advanced platforms, aligning with the accelerated development timelines observed in some AI-driven drug discovery efforts.
• The pro forma cash of $14 million post-merger and offering provides initial operational runway, which is typical for early-stage biopharma companies, but suggests that further capital raises will likely be necessary to fund extensive clinical development.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Face significant dilution from the public offering and the anti-dilution adjustment for preferred stock conversion. Future value is highly dependent on the successful clinical development and commercialization of Decoy's R&D programs.
• Former Decoy Stockholders/Debtholders: Received Series A and B Preferred Stock, which are subject to anti-dilution protection but require future stockholder and Nasdaq approval for conversion to common stock, introducing a waiting period and uncertainty regarding liquidity and ultimate common share ownership.
• Employees: A new management team from Decoy has taken key leadership roles, which may lead to organizational restructuring and changes in corporate culture. The combined entity offers new R&D opportunities.
• Creditors: Decoy's outstanding promissory notes will be paid off using proceeds from the offering, which is positive for those specific creditors.
• Customers/Patients: The merger aims to accelerate the development of new therapeutics, potentially benefiting future patients in respiratory infectious diseases and GI cancers by bringing innovative treatments to market faster.

Next Steps

• Advance the clinical development of the combined company's research and development programs.
• Pay off certain of Decoy Therapeutics Inc.'s outstanding promissory notes as required.
• Utilize net proceeds for general corporate purposes, including working capital, research and development, and capital expenditures.
• File an Investigational New Drug (IND) application with the FDA for the lead pan-coronavirus antiviral asset within the next 12 months.
• Make progress on other programs, including a broad-acting antiviral for flu, COVID-19, and RSV, and a peptide drug conjugate targeting GI cancers.
• Call a special stockholder meeting to approve the conversion of the Preferred Stock issued at merger closing into shares of Salarius common stock.
• Obtain Nasdaq approval for the combined company's initial listing application.
• Rename the new company to Decoy Therapeutics.

Key Dates

Recommendation

The significant dilution from the public offering, coupled with the anti-dilution adjustment for the preferred stock that further increases potential dilution for common shareholders, presents a substantial negative impact on existing common stock value. While the merger with Decoy and the capital raise provide a new strategic direction and funding for innovative R&D, the immediate and future dilution risks outweigh the speculative benefits of the preclinical pipeline for a seasoned investor. The need for future stockholder approval for preferred stock conversion also adds an element of uncertainty and potential for further delays or complications. Given the current financial structure and the early stage of Decoy's pipeline, the risk-reward profile is unfavorable for existing common shareholders.

Keywords

Salarius Pharmaceuticals, Decoy Therapeutics, Merger, Public Offering, Common Stock, Warrants, Pre-funded Warrants, Series A Warrants, Series B Warrants, Biopharmaceutical, Clinical-stage, AI drug discovery, Machine Learning, Peptide conjugate therapeutics, IND application, Pan-coronavirus antiviral, GI cancers, Nasdaq, Capital raise, Dilution, Corporate governance, Management change, Frederick E. Pierce, Barbara Hibner, Peter Marschel, Mark Rosenblum